Remission and outcome
| Characteristic . | Azacitidine, n = 587 . | LDAC, n = 67 . |
|---|---|---|
| Best response | ||
| CR | 272 (47%) | 38 (58%) |
| CRi | 114 (20%) | 10 (15%) |
| Morphologic leukemia-free state | 21 (3.7%) | 0 (0%) |
| Partial remission | 61 (11%) | 1 (1.5%) |
| Refractory disease | 62 (11%) | 11 (17%) |
| Death before response assessment | 44 (7.7%) | 6 (9.1%) |
| Missing | 13 | 1 |
| Day 30 mortality | 5% | 6% |
| Day 60 mortality | 8% | 7% |
| Allogeneic transplant | 35 (6.0%) | 4 (6.0%) |
| In CR1 | 32 (5.5%) | 3 (4.5%) |
| OS | ||
| Median survival (mo) | 13.6 (95% CI, 11.7-15.1) | 10.9 (95% CI, 8.8-20.2) |
| 12-mo survival | 54% | 46% |
| Characteristic . | Azacitidine, n = 587 . | LDAC, n = 67 . |
|---|---|---|
| Best response | ||
| CR | 272 (47%) | 38 (58%) |
| CRi | 114 (20%) | 10 (15%) |
| Morphologic leukemia-free state | 21 (3.7%) | 0 (0%) |
| Partial remission | 61 (11%) | 1 (1.5%) |
| Refractory disease | 62 (11%) | 11 (17%) |
| Death before response assessment | 44 (7.7%) | 6 (9.1%) |
| Missing | 13 | 1 |
| Day 30 mortality | 5% | 6% |
| Day 60 mortality | 8% | 7% |
| Allogeneic transplant | 35 (6.0%) | 4 (6.0%) |
| In CR1 | 32 (5.5%) | 3 (4.5%) |
| OS | ||
| Median survival (mo) | 13.6 (95% CI, 11.7-15.1) | 10.9 (95% CI, 8.8-20.2) |
| 12-mo survival | 54% | 46% |